Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.
As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.
Publication Alerts
Subscribe to receive alerts once a paper has been published by Oncotarget.
On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control.
This malicious action will be reported to the FBI.
On August 25, 2022, the Office of Science and Technology Policy announced a new government policy legislating the immediate public release of all United States-funded research publications by 2025. Learn more here and here.
On May 23, 2023, the Council of the European Union adopted conclusions on high-quality, transparent, open, trustworthy, and equitable scholarly publishing. The Council calls for immediate and unrestricted open access to publishing research involving public funds. Learn more.
The COVID-19 pandemic has killed over one million Americans with many dying during the Omicron wave. By now most Americans have either had COVID-19 and/or been vaccinated against it. Despite the availability of updated immunizations, only 16.7% of Americans are now up-to-date on bivalent boosters. In their new editorial, researchers Thomas A. Ollila, Rashida Taher and Prashanth Moku from the Alpert Medical School of Brown University and Rhode Island Hospital discuss the current state of COVID-19 treatment.
“At our cancer center, we treat many patients with hematologic malignancies, most of whom are older adults.”
Patients with hematologic malignancies, especially lymphoma, are at increased risk of poor response to vaccination and worse outcomes from COVID-19 infection. The researchers state that most of their patients have been abundantly cautious since the onset of the pandemic and some have avoided ever becoming infected. Patients in their clinic frequently inquire about the safety of being outdoors, spending time with their families during large gatherings (Christmas, Thanksgiving, etc.), and methods to prevent the contraction of COVID-19.
“Despite these precautions, too many patients reached remission from cancer only to then perish from COVID-19 in the first years of the pandemic.”
The concerns behind their questions are very real, but understanding how to best answer them is not always easy and their abundance of caution is not without cost. Grandchildren’s birthdays went uncelebrated, weddings were forgone, and memorable moments with loved ones were lost. With both aging and malignancy, an acute awareness of the limited days means that there may not be years ahead to make up for all that was missed.
“Although COVID-19 continues to pose a serious threat, medical advancements have now allowed for a more in-depth risk-benefit discussion to weigh the risk of infection versus the challenges of social isolation.”
About Oncotarget: Oncotarget (a primarily oncology-focused, peer-reviewed, open-access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
